[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

World Epilepsy Therapeutics Market to Reach USD 7.5 Bn in 2026, Expects GlobalData in Its In-Demand Topical Report Available at MarketPublishers.com

22 Jan 2018 • by Natalie Aster

LONDON – There are a range of marketed anti-epileptic drugs (AEDs), with an older generation completely genericized in the USA, Germany, France, Italy, the UK, Spain and Japan (7MM) and a 2nd generation, which are covered under patent protection.

There are 5 late-stage drug products in the pipeline, which address certain unmet needs in the marketplace and, in this regard, are poised to stimulate growth whilst patent expirations for leading brand will likely act as a hindrance to the epilepsy market’s growth in the years to come.

The sales of AEDs in 2016 stood at close to USD 6.1 billion across the 7MM. Through to 2026, the market is set to amount to a value of USD 7.5 billion, registering a 2.1% CAGR over the forecast period. This growth is projected to be fuelled by the launch of 5 late-stage pipeline drugs. GW Pharmaceuticals’ Epidiolex (cannabidiol) and Zogenix’s flenfluramine are anticipated to be the two top-selling drugs, with both targeting rare, orphan epilepsy syndrome.

Topical research report “PharmaPoint: Epilepsy - Global Drug Forecast and Market Analysis to 2026” drawn up by GlobalData provides an all-round examination of the market landscape and dynamics across the 7MM.

The study gives relevant information on the disease etiology, diagnosis, epidemiology, pathophysiology, symptoms and management. It gives updated statistics on epilepsy therapeutics market revenues on an annual basis, cost of therapy per patient and treatment usage patterns across 3 patient segments, during 2016-2026. Furthermore, the report provides a strategic competitor analysis, identifies the actual unmet needs in the sector, provides a mapping of clinical trials, etc. The research study presents comprehensive data shedding light on emerging trends and MoA under development for epilepsy therapy; it profiles the most promising candidates in Phase III trials. It examines the current and future market competition in the world epilepsy therapeutics marketplace. A complete analysis of key industry drivers, hindrances and challenges is included, too.

Many other topical research reports by this publisher are at hand in GlobalData online catalogue at MarketPublishers.com.


The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]


Analytics & News

Weekly Digest